Compare Novo Nordisk A/S (NVO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oatly Group AB - ADR — how do they compare? Novo Nordisk A/S trades at $38.4 (market cap $165.31B), while Oatly Group AB - ADR trades at $10.46 (market cap $330.93M). The key difference: Novo Nordisk A/S is far larger — about 499.5× Oatly Group AB - ADR's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Oatly Group AB - ADR for 18 Days on average.
| NVO | OTLY | |
|---|---|---|
Market Cap | $165.31B | $330.93M |
Volume | 11,432,838 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $15.91 |
52-Week Low | $35.29 | $8.03 |
Typical Hold Time | 116 Days | 18 Days |
Enterprise Value | $179.56B | $835.34M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Oatly (OTLY) trades at $10.42, up 0.48% on the day, amid mixed technical signals and ongoing fundamental challenges. The stock shows a bearish moving average trend but bullish oscillators, with key support at $10. Revenue growth is steady, reaching $862.46M in 2025, yet profitability remains elusive with a net income margin of -13.81%. Recent Q2 2026 results beat expectations, and management raised full-year revenue guidance, driving positive sentiment from some analysts.
The outlook is cautiously optimistic, with a consensus price target of $12.28 suggesting 18% upside, but significant risks persist. High debt levels, negative cash flows, and intense competition in the plant-based food sector threaten near-term stability. Investors should weigh the potential for operational turnaround against persistent losses and leverage concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
